coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    East Warrington PCN, Warrington (LAD) · Health Inequalities Profile

    PCN U14045 · NHS Cheshire and Merseyside Integrated Care Board · 3 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    29,894

    Registered population

    60.4% aged 18–64

    20.7%

    Aged 65+

    ICB 19.0% · England 17.9%

    6.0%

    Ethnic minority (non-White)

    2.6% Asian · England 9.6%

    29.3%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    ~10,702

    Core20 residents (est.)

    Resident basis; registered basis ~8,736 · see page 3

    5,435

    Hypertension register

    +7.84% in 3 yrs · England +5.60%

    314

    SMI register

    14.1% of Warrington (LAD)'s

    698

    COPD register

    Reviews -5.42% in 3 yrs

    Forecast to 2030

    6,218

    Hypertension patients, 2030

    +783 on today

    73.5%

    QRISK ≥20% on statins, 2030

    +5.29pp over 3 yrs

    4.9%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    34.6 pp
    Phone access varies sharply between practices.

    Easy phone contact spans 34.6 pp from 32.2% at Fearnhead Cross Med.ctr. to 66.8% at Padgate Medical Centre, which could reflect demand pressures.

    65.9%
    Diabetic statin therapy and BP control lag.

    Statin treatment in diabetes aged 40+ without CVD is 65.9% (England 73.2%) and under-80 BP control is 65.0% (England 67.8%), suggesting review gaps.

    +12.2%
    Breast screening growth outpaced national average.

    Breast screening coverage for ages 53 to 70 rose +12.2% from 2023 to 2024 (England +8.4%), reaching 71.3% against 69.9% across England.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Registered patients aged 65+ reach 20.7%, yet recorded dementia prevalence is 0.5%

    East Warrington PCN has 29,894 registered patients across three practices. Patients aged 65+ make up 20.7% (6,185 patients), above Warrington (LAD) (17.5 percent), NHS Cheshire and Merseyside ICB (19.0 percent) and England (17.9 percent). Area Census estimates of usual residents, rather than registered patients, record 94.0% White (Warrington (LAD) 93.5 percent, ICB 93.0 percent, England 81.1 percent) and 6.0% ethnic minorities. Across 14 catchment care homes (448 beds), recorded dementia prevalence is 0.5% (157 patients), below Warrington (LAD) (0.9 percent), the ICB (0.9 percent) and England (0.8 percent), leaving an unadjusted gap of +77 to +112 patients.

    Age profile

    0–1718.9%
    18–6460.4%
    65+20.7%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White94.0%
    Asian2.6%
    Mixed1.5%
    Other1.0%
    Black0.9%

    Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Warrington LA)1,7372,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.8%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)56.8%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Warrington LA)9051,0219552024/25
    Falls deaths, all ages, per 100,000 (Warrington LA)12.118.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation reaches 29.3% PCN-wide and varies by 28.7 pp across practices

    The PCN Core20 share is 29.3%, above Warrington (LAD) (16.9 percent) and England (21.0 percent), with an average IMD decile of 5.1. The range in Core20 prevalence across captured practices is 28.7 pp. Fearnhead Cross Med.ctr. has a Core20 share of 41.0%, representing an estimated 5,156 patients. Birchwood Medical Centre has a Core20 share of 26.2%. Padgate Medical Centre has a Core20 share of 12.3%. Across the PCN, 2 practices have a Core20 share above England. The estimated resident population in IMD deciles 1 and 2 is 10,702.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Fearnhead Cross41.0% · 5,156 patients
    Birchwood26.2% · 2,731 patients
    Padgate12.3% · 849 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    314

    SMI register

    1.01% recorded prevalence

    194

    Learning disability register

    0.63% recorded prevalence

    14

    Care homes, 448 beds

    In the PCN catchment

    9.4%

    Provide unpaid care

    Warrington (LAD), Census 2021

    The PCN records 314 severe mental illness patients (1.0%, matching England's 1.0%) and 194 learning disability patients (0.6%, matching England's 0.6%), representing 14.1% and 15.8% of borough registers alongside 14 catchment care homes (448 beds). With recorded prevalence matching national benchmarks, sustaining annual physical health checks and structured reviews across these vulnerable groups is the primary operational priority.

    Severe mental illness: physical health checks

    SMI blood pressure coverage is 88.1% (England 83.4%). BMI recording fell 3.7 pp to 81.7% (England +5.1 pp), trailing at Padgate Medical Centre (65.5%) and Fearnhead Cross Med.ctr. (78.9%), while alcohol recording fell 3.9 pp (England +5.4 pp).

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,435

    Hypertension register

    +7.84%

    Register growth, 3 yrs

    Warrington (LAD) +6.41% · England +5.60%

    +0.11pp

    BP control, under 80

    ≤140/90 · +3.94pp aged 80+

    +783

    More patients by 2030

    Forecast 6,218 (20.37%)

    Hypertension case-finding and control

    Recorded hypertension prevalence is 17.5% (5,435 patients), above Warrington (16.4%), the ICB (16.8%) and England (15.2%), with 3-year growth of +7.8% (England +5.6%). While 88.7% have a recent blood pressure reading, control under age 80 is 65.0%, below England (67.8%), Warrington (66.5%) and the ICB (66.4%), rising +0.2% over three years (England +3.2%). Control under 80 reaches 72.8% at Fearnhead Cross Med.ctr., but trails at Birchwood Medical Centre (59.9%) and Padgate Medical Centre (58.9%). Implied register denominators differ from list sizes, and figures include personalised care adjustments. Lagging blood pressure control under age 80 indicates an opportunity to prioritise clinical treatment escalation and structured recall at the two lowest-achieving practices.

    Lipids and statins

    Statin coverage in diabetes aged 40 and over without cardiovascular disease is 65.9%, trailing England (73.2%), Warrington (69.8%) and the ICB (72.4%). Primary prevention for QRISK ≥ 20% is 61.4% (England 63.6%). Fewer at-risk patients receive lipid-lowering therapy than national benchmarks imply, so proactive recall audits should prioritise diabetic primary prevention.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202651,897£1.50£1.71£1.86£77,846
    Cardiovascular (all), 202577,684£5.31£4.37£3.33£412,502

    In 2026, the PCN prescribed 51,897 lipid-regulating items at £1.50 per item, below England (£1.86), Warrington (£1.59) and the ICB (£1.71). This spend is £18,683 less than at England's unit cost, across 51,897 items. Lower unit costs than England could allow the PCN to expand lipid therapy coverage without exceeding benchmark expenditure.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +3.14%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −1.59%

    Asthma prevalence, PCN 3-yr % change

    COPD prevalence is 2.2% (698 patients; England 1.9%), but annual reviews fell 5.4% over three years to 71.5% (England 76.4%, +2.8%), lowest at Birchwood Medical Centre (65.7%). Asthma prevalence is 7.8% (2,302 patients; England 6.6%), with annual review coverage at 66.6% (England 65.7%), leaving about 770 patients unreviewed. Asthma prescribing in ages 5-19 reaches 2,119 per 1,000 (England 1,488; Warrington (LAD) 1,534). This pattern may reflect routine review gaps, unverified locally; clinical audits would test this.

    Cancer register and children's immunisation

    The cancer register records 1,215 patients (3.9%; England 3.8%), growing +11.8% over three years (England +9.0%). For pre-school immunisation, MMR dose 1 reaches 98.2% at age 5 (England 91.7%), but dose 2 drops to 87.5% (England 82.8%), a 10.7 pp same-cohort drop that widens to 17.6 pp at Padgate Medical Centre (76.5%). Timely pre-school recall is essential to avoid under-immunisation before school entry.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months94.3%

    England 91.0%

    6-in-1 complete primary course at 24 months94.9%

    England 92.2%

    MMR dose 1 at 24 months93.2%

    England 88.3%

    MMR dose 2 at age 587.5%

    England 82.8%

    4-in-1 pre-school booster at age 587.5%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In 2022, 55.5% of cancers with a known stage (7,482 of 13,490) in NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2, compared with 55.3% in England, remaining 19.5 pp below the 75.0% national ambition by 2028. Known-stage completeness was 72.8% (13,490 of 18,522 registrations; England 67.0%). Closing this gap would require about 2,640 additional early diagnoses across the ICB. These system metrics describe the ICB rather than PCN performance. Primary care contributes through screening and early detection; PCN cervical screening is 70.6% (Warrington (LAD) 71.6%), but Fearnhead Cross Med.ctr. records 68.8%.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026, North Cheshire and Mersey NHS Foundation Trust achieved 83.7% against the 85.0% 62-day cancer standard (1.3 pp below target), outperforming Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), NHS Cheshire and Merseyside Integrated Care Board (76.2%) and England (71.2%). The trust met the 28-day faster diagnosis standard at 80.2% (target 75.0%) and the 31-day standard at 98.2% (target 96.0%). In diagnostics, 6.3% waited 6+ weeks (England 23.1%), though colonoscopy was 16.0%. These reflect provider performance, not PCN activity.

    Pathways within standard (%)North Cheshire and MerseyMersey and West LancashireManchesterCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)80.2172.3980.0677.2579.32
    31-day treatment (96%)98.1795.4692.5495.7192.50
    62-day referral to treatment (85%)83.6777.9672.8576.2371.16
    Diagnostic waits over 6 weeks (%)North Cheshire and MerseyMersey and West LancashireManchesterEngland
    MRI0.5314.0411.6821.40
    CT2.3213.0814.669.92
    Echocardiography28.0434.884.9128.48
    Colonoscopy15.9818.044.5130.83
    Gastroscopy20.2418.1729.3529.02
    All 15 DM01 tests6.3421.178.9823.14
    Community services activityWarrington residentsCheshire and Merseyside ICB
    Care contacts38,550541,280
    Referrals7,32097,150
    Patients with a contact14,830146,240

    Community services (residents of Warrington), Jun 2026 (provisional). In June 2026, provisional community services data recorded 38,550 care contacts and 358,950 care activities for Warrington residents, alongside 1,332,205 activities across NHS Cheshire and Merseyside Integrated Care Board. Adults aged 65+ accounted for 56% of Warrington contacts (21,595 of 38,550). These experimental figures reflect submitting providers and resident activity rather than PCN-specific caseloads.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Patient phone access varies by 34.6 pp across practices alongside uneven overall experience

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Padgate9012.366.8%62.4%77.8%
    Birchwood11526.238.9%76.8%72.1%
    Fearnhead Cross10141.032.2%70.6%68.0%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNWarrington (LAD)AssetPCNWarrington (LAD)
    Care homes (catchment)14 (448 beds)n/aSchools (catchment)69n/a
    Children's centres612Places of worship2689
    Libraries17Primary schools (LA maintained)1328
    Primary academies1431Special schools11

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Respiratory annual review recall

    Asthma review coverage is 66.6% of 2,302 patients (leaving 768, or about 770, unreviewed); COPD reviews fell 5.4% to 71.5% (England 76.4%), lowest at Birchwood Medical Centre (65.7%). For discussion: introduce single-template respiratory recall and flexible review slots across the 2,302 asthma and 698 COPD patients. Moderate effort to run.

    Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.

    Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.

    Option 2

    Cardiovascular control and statin recall

    BP control under 80 is 65.0% (England 67.8%), trailing at Padgate Medical Centre (58.9%) and Birchwood Medical Centre (59.9%); diabetic statin coverage is 65.9% (England 73.2%). For discussion: run pharmacist-led recall and titration reviews for uncontrolled hypertension and eligible diabetes or QRISK >=20% (61.4%) patients. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Dementia case-finding and care home review

    Recorded dementia prevalence is 0.5% (157 patients) vs 0.8% in England and 0.9% in Warrington (LAD), an unadjusted gap of +77 to +112 patients despite 20.7% aged 65+. For discussion: audit clinical records for uncoded dementia diagnoses and conduct structured case-finding across the 14 catchment care homes (448 beds). Moderate effort to run.

    Evidence base: dementia diagnosis rates lag in deprived and minority ethnic populations and in care homes; the register is the cohort for diagnosis-rate improvement and the annual dementia review, and diagnosis and post-diagnostic support delay care-home entry.

    Policy anchor: national dementia diagnosis-rate ambition of 66.7%; 95% of people with complex needs to have an agreed care plan by 2027.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Dementia register and coding review (p2)Dementia: QOF prevalence66.7% diagnosis ambition · 95% care plan 2027PCN
    Targeted Core20 proactive outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    SMI health check audit (p4)Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension control recall audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school MMR recall review (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Targeted cervical screening recall (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Telephony access and triage review (p9)GPPS easy to contact the practice by phone10YHP, hospital to communityPractice
    Option 1 · Respiratory annual review recall (p12)COPD register · Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN & Practice
    Option 2 · Cardiovascular control and statin recall (p12)Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN & Practice
    Option 3 · Dementia case-finding and care home review (p12)Dementia register · Dementia: QOF prevalence · Aged 65+66.7% diagnosis ambition · 95% care plan 2027PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15